PRINTBIO
LIVE

Serial Number

98638778

Owner

PrintBio, Inc.

Attorney

Jared L. DuJack

Filing Date

Jul 9, 2024

Add to watchlist:

No watchlists yet
View on USPTO

PRINTBIO Trademark

Serial Number: 98638778

PRINTBIO is a trademark filed by PrintBio, Inc. on July 9, 2024. The trademark is classified under Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 7 (Machinery), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

PrintBio, Inc. (9 trademarks)

9511 Collins Avenue #1403
Surfside, FL 33154

Entity Type: 03

Trademark Details

Filing Date

July 9, 2024

Registration Date

Not Registered

Published for Opposition

March 24, 2026

Goods & Services

Collagen preparations for cosmetic purposes

Implants and mesh made of synthetic materials for use in soft tissue repair or the reconstruction of soft tissue deficiencies; Implantable protective shells composed of synthetic material; Implantable structural support devices composed of synthetic material; Bioprinted organs comprising primarily synthetic material for medical use; Bioprinted organs, namely, ears comprising primarily synthetic material for medical use; Bioprinted organs, namely, livers comprising primarily synthetic material for medical use; Bioprinted organs, namely, kidneys comprising primarily synthetic material for medical use; Bioprinted organs, namely, portions of ears comprising primarily synthetic material for medical use; Bioprinted organs, namely, portions of livers comprising primarily synthetic material for medical use; Bioprinted organs, namely, portions of kidneys comprising primarily synthetic material for medical use; Autologous bioprinted organs comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, ears comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, livers comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, kidneys comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, portions of ears comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, portions of livers comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, portions of kidneys comprising primarily synthetic material for medical use; Bioprinted structures for organs comprising primarily synthetic material for medical use; Autologous bioprinted structures for organs comprising primarily synthetic material for medical use; Ink for 3D bioprinters comprising primarily synthetic material or other materials for medical purposes; Implantable protective shells comprising primarily synthetic material; Implantable structural support devices comprising primarily synthetic material; Implantable bioprinted exoskeletons comprising primarily synthetic material; Implantable 3D bioprinted exoskeletons comprising primarily synthetic material; Bioprinted surgical mesh comprising primarily synthetic material; Bioresorbable surgical mesh comprising primarily synthetic material; Bioprinted bioresorbable surgical mesh comprising primarily synthetic material

Medical services, namely, organ replacement therapy; Medical services, namely, organ replacement therapy using 3D bioprinting; Medical services, namely, organ replacement therapy using autologous bioprinting; Medical services, namely, on demand organ replacement therapy; Medical services, namely, on demand organ replacement therapy using 3D bioprinting; Medical services, namely, on demand organ replacement therapy using autologous bioprinting

3D bioprinters; 6-axis 3D bioprinters

Collagen for scientific and research use

Bioprinted organs comprising primarily living tissue for medical use; Bioprinted organs, namely, ears comprising primarily living tissue for medical use; Bioprinted organs, namely, livers comprising primarily living tissue for medical use; Bioprinted organs, namely, kidneys comprising primarily living tissue for medical use; Bioprinted organs, namely, portions of ears comprising primarily living tissue for medical use; Bioprinted organs, namely, portions of livers comprising primarily living tissue for medical use; Bioprinted organs, namely, portions of kidneys comprising primarily living tissue for medical use; Autologous bioprinted organs comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, ears comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, livers comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, kidneys comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, portions of ears comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, portions of livers comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, portions of kidneys comprising primarily living tissue for medical use; Bioprinted structures for organs comprising primarily living tissue for medical use; Autologous bioprinted structures for organs comprising primarily living tissue for medical use; Ink for 3D bioprinters comprising primarily living cells or other biological materials for medical purposes; Implantable protective shells comprising primarily living tissue; Implantable structural support devices comprising primarily living tissue; Implantable bioprinted exoskeletons comprising primarily living tissue; Implantable 3D bioprinted exoskeletons comprising primarily living tissue; Bioprinted surgical mesh comprising primarily living tissue; Bioresorbable surgical mesh comprising primarily living tissue; Bioprinted bioresorbable surgical mesh comprising primarily living tissue; Collagen for medical purposes; Collagen for medical purposes, namely, wound healing

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 19, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 24, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 24, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 18, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 28, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 27, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 27, 2026 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 27, 2026 ERFR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Dec 2, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Dec 2, 2025 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 2, 2025 GNFN
FINAL REFUSAL E-MAILED
Sep 2, 2025 GNFR
FINAL REFUSAL WRITTEN
Sep 2, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 21, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 21, 2025 CRFA
ASSIGNED TO LIE
Aug 21, 2025 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 8, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
May 8, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
May 8, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 8, 2025 GNRN
NON-FINAL ACTION E-MAILED
Feb 8, 2025 GNRT
NON-FINAL ACTION WRITTEN
Feb 8, 2025 CNRT
ASSIGNED TO EXAMINER
Feb 1, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 31, 2025 NWOS
NEW APPLICATION ENTERED
Jul 9, 2024 NWAP